GW Pharmaceuticals announces EPIDYOLEX reclassified as a Schedule 5 drug

GW's cannabis-based medicine rescheduled following approval by the European Medicines Agency.

GW Pharmaceuticals plc (NYSE: GWPH), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the UK Home Office has reclassified EPIDYOLEX (cannabidiol) as a Schedule 5 drug. This change will take effect immediately in all four of the constituent nations of the UK – with Northern Ireland enacting separate legislation1 – and sees the medicine move from Schedule 2 to Schedule 5 under the Misuse of Drugs Regulations 2001.

We remain committed to expanding the high-quality evidence base for cannabis-based medicines and securing further regulatory approvals because doing so is in the interests of patients and healthcare professionals and can support further rescheduling.Chris Tovey, GW's Chief Operating Officer

"The decision to move EPIDYOLEX to a low level of control is an important one for patients, their families, healthcare professionals, pharmacists and the NHS as a whole – reducing costs and ensuring the medicine can be dispensed more easily," said Chris Tovey, GW's Chief Operating Officer. "The extensive pre-clinical and clinical data that GW developed to support the medicine's approval by regulatory authorities was pivotal to this important schedule change, and we would like to thank the MHRA, ACMD and Home Office for scrutinising this data and making this change in such a short timeframe."

The ACMD and its Technical Committee recommended the schedule change to Kit Malthouse MP, Minister of State for Crime and Policing, on 29 January 2020. This followed the submission of a written dossier and oral presentation from the MHRA, which drew on the substantial data package developed by GW as part of the medicine's review and subsequent approval by the regulatory authorities in September 2019. The medicine is approved in the EU for adjunctive therapy of seizures associated with Lennox Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, for patients from 2 years of age and older.

In its recommendation to the Minister, the ACMD cited the "low risk of abuse potential, low risk of dependency and low risk of diversion" as reasons for the reclassification from a schedule 2 controlled drug to a schedule 5 controlled drug.2 The ACMD also cautioned that GW's medicine is "distinct from other commercially available CBD containing supplements that have not sought marketing authorisation as a medicine" and that the schedule change, therefore, applies exclusively to EPIDYOLEX.

The recommendation was accepted by the Minister on 22 April 2020 and secondary legislation was tabled to enact the change on 3 June 2020.GW's medicine is now exempt from virtually all controlled drug requirements.4 Patients and their families will now have greater flexibility on the quantity of medicine they can receive and be able to benefit from repeat prescriptions, thereby potentially reducing travel to hospital pharmacies, whilst healthcare professionals and pharmacists will benefit from reduced controls around the storage and reporting requirements that exist for medicines under Schedule 2.

To learn more about GW Pharmaceuticals, visit the company HQ here.

Disclaimer: Past performance is not an indicator of future performance.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Casey Peternell
Casey Peternell

Casey is a media and content creator with a keen eye for creativity. Casey is currently in the process of obtaining a double bachelors degree in Media & Communications and Business from Swinburne University in Melbourne.

Leave a Reply

Your email address will not be published. Required fields are marked *